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Introduction: Surgery is the standard treatment for early stage non–
small-cell lung cancer (NSCLC). For medically inoperable patients, 
stereotactic ablative radiotherapy (SABR) has emerged as widely 
used standard treatment. The aim of this study was to analyze sur-
vival and patterns of tumor recurrence in patients with clinical stage 
I NSCLC treated with surgery or SABR.
Methods: Clinical data from all subsequent fluoro-deoxyglucose 
positron emission tomography/computed tomography-based stage 
I NSCLC patients (cT1-T2aN0M0) treated with surgery or SABR 
at our center between 2007 and 2010 were collected. Primary end-
points were overall survival and tumor recurrences/new primary lung 
tumors. Treatment groups were compared using multivariable Cox 
regression and competing risk analyses.
Results: Three hundred-forty patients treated with surgery (n = 143) 
or SABR (n = 197) were included. Surgical patients were younger, 
had a better WHO performance status and less comorbidities. After 
adjustment for prognostic covariables, treatment did not influence 
overall survival (adjusted hazard ratio [HR], SABR versus surgery 
1.07; 95% confidence interval [CI]: 0.74–1.54; p = 0.73). Local con-
trol and distant recurrence were equal, whereas locoregional recur-
rences were significantly more frequent after SABR compared with 
surgery (adjusted sub-HR 2.51; 95% CI: 1.10–5.70; p = 0.028). 
Nodal failure (HR: 2.16; 95% CI: 1.34–3.48) and distant metastases 
(HR: 2.12; 95% CI: 1.52–2.97), but not local failure (HR: 1.00; 95% 
CI: 0.53–1.89) predicted overall survival.
Conclusions: In patients with fluoro-deoxyglucose positron emis-
sion tomography/computed tomography-based stage I NSCLC, 
SABR confers worse locoregional tumor control because of more 
nodal failures compared with surgery, stressing the need to improve 
mediastinal and hilar staging.
Key Words: Non–small-cell lung cancer, Early stage NSCLC, 
Lobectomy, Stereotactic radiotherapy.
(J Thorac Oncol. 2015;10: 826–831)
Lobectomy with systematic lymph node dissection is the standard procedure for medically operable patients with 
stage I non–small-cell lung cancer (NSCLC), with a 5-year 
survival of 50% to 70%.1,2 A considerable part of patients 
with resectable early stage NSCLC is however medically 
inoperable because of frailty or severe comorbidity.3 In a 
cohort of 10,984 patients with early stage NSCLC, surgery 
was not performed in 23.3% of the white patients and 36% 
of the black patients. This included inoperable patients as 
well as patients refusing surgery.4 The most common rea-
sons for medical inoperability are poor lung function, which 
is often seen in COPD patients, or cardiovascular comor-
bidity, both of which bring about an increased risk of post-
operative pulmonary complications. When withholding 
inoperable patients any antitumor treatment, the prognosis 
is poor and most of them will die because of tumor progres-
sion. The 5-year overall survival in untreated patients is 6% 
or less.3,5
From the late 1990s, technological improvements of 
radiotherapy planning software, verification devices, together 
with advanced planning-CT techniques (4D-CT) made stereo-
tactic treatment of small tumor volumes with very high doses 
per fraction possible. With stereotactic ablative radiotherapy 
(SABR), higher dose in just a few fractions can be deliv-
ered and surrounding tissue is much better spared than with 
3D-conformal radiotherapy.6,7 In patients with stage I NSCLC, 
overall survival and local control rates after SABR are better 
compared with rates found after conventional 3D-conformal 
radiotherapy.8
Potential clinical advantages of SABR over surgery are 
the absence of an invasive procedure with possible associated 
complications, anesthesia, and hospital admission. However, 
no randomized trials comparing clinical outcomes after either 
procedure are available.
Several studies have been performed regarding the 
effect of SABR on survival and tumor control. Soldà et al.9 
reviewed 45 reports analyzing SABR in patients with stage 
I NSCLC and found survival rates similar to those in a large 
matched surgical cohort.
A recent large single-center retrospective study, in 
contrast, found lower 3-year overall survival rates for SABR 
compared with surgical patients.10 Local tumor control after 
SABR is generally good, with previously reported rates rang-
ing between 85% and 98%.9–14 Few studies were performed 
comparing the outcomes of a SABR cohort directly with a 
primarily operable surgical cohort.10,14–17
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We performed a retrospective study in a large consecu-
tive cohort of patients with clinical stage I NSCLC treated 
at a single university medical center with surgery or SABR, 
with the aim to compare survival rates and patterns of tumor 
recurrence. Comorbidity, age, and performance status were 
the factors upon which treatment allocation had been based 
at the multidisciplinary pulmonary oncology panel. Thus, all 
analyses were adjusted for these factors.
Because of patient selection, we hypothesized a signifi-
cantly worse unadjusted survival for the SABR cohort that 
should be equalized after adjustment. Also, we expected com-
parable adjusted local, locoregional, and distant tumor recur-




The study was conducted at the University Medical 
Center Groningen in the Netherlands. Because all data in this 
study were obtained from patient medical records and patients 
themselves were not involved in the study, neither approval 
of the Institutional Review Board nor informed consent were 
required according to Dutch law.
All consecutive patients treated between January 2007 
and July 2010 with curatively intended surgery or SABR for 
proven or suspected fluoro-deoxyglucose positron emission 
tomography–computed tomography (FDG-PET–CT)-staged 
NSCLC were selected from the database.
Inclusion and Exclusion Criteria
Patients with cT1-2aN0M0 tumors (less than 50 mm) 
according to the 7th TNM edition were included18 (Fig. 1). 
Staging was based on FDG-PET/CT. Furthermore, inclusion 
required cytological or histological confirmation of the tumor 
or, in absence of a pathological confirmation, a combination 
of imaging information requiring increased FDG-PET-uptake 
and/or a growing or new lesion on CT exhibiting signs of 
malignancy. FDG-avid or CT-enlarged (greater than 10 mm 
short axis diameter) lymph nodes were examined with medi-
astinoscopy or endosonography with fine-needle aspiration to 
confirm that their nodes are free of tumor. Patients with a pre-
operatively proven benign lesion, lung metastases, small-cell 
lung cancer, or lymph node metastases were not included as 
well as patients with neoadjuvant chemotherapy or radiother-
apy (Fig. 1). Patient allocation to treatment required discus-
sion at the multidisciplinary pulmonary oncology panel.
Treatment Procedures
Surgery was performed via open thoracotomy (94% of the 
cases) or video-assisted thoracic surgery and included wedge 
resection, lobectomy, bilobectomy, or pneumonectomy, the lat-
ter three operations with hilar and mediastinal lymph-node dis-
section. SABR was based on a 4D-planning CT. The planning 
target volume (PTV) was defined as the envelope including the 
moving gross tumor volume plus a margin in all directions of 
5 mm. After the institutional protocol, a risk-adapted fraction-
ation schedule of 3 to 12 fractions to 60 Gy was administered 
using a Novalis accelerator, online position verification and 
correction was performed using the Exac-Trac system with a 
6D-robotic couch (Brainlab, Feldkirchen, Germany).8 In brief, 
lesions completely surrounded by lung tissue and not located 
within 2 cm of the central airways received three fractions of 
20 Gy. Lesions located within the 2 cm corridor of trachea and 
main bronchi received eight fractions of 7.5 Gy or 12 fractions 
of 5 Gy, whereas lesions adjacent to the thoracic wall received 
five times 12 Gy. During the study period, a pencil-beam dose-
calculation algorithm with tissue heterogeneity correction had 
been used and the dose was prescribed at 80% isodose com-
prising periphery of the PTV.8
Follow-Up
Patient data were extracted from the hospital patient 
files and supplementary information was retrieved via 
FIGURE 1.  Consort diagram.
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telephone contact with general practitioners. Patients’ vital 
status was additionally obtained from the Municipal Personal 
Records Database with a cutoff on January 30, 2014. During 
follow-up, regular CT scans were made to monitor tumor 
recurrences 3 and 6 months after treatment, then at 6 months 
intervals until 2 years and yearly thereafter. FDG-PET was 
only performed when clinically indicated. Tumor recurrence 
was scored in case of greater than 20% tumor growth (after 
SABR), new lesions on CT or brain MRI, or a confirmatory 
FDG-PET showing high FDG uptake in the lesion.
Study Endpoints
The endpoints of the study were overall survival and 
local, nodal, locoregional (=local or nodal or both), and dis-
tant tumor recurrence or new pulmonary tumors. To score 
local recurrence in a study comprising patients with lobec-
tomy, pneumonectomy, wedge resection, and SABR is highly 
challenging. In this study, local recurrence after both surgery 
and SABR was defined as a growing tumor in the same lobe as 
the primary tumor including growth at the irradiated location 
(the PTV) or around the surgical clips including the ipsilateral 
hilus. Tumor occurring in another lobe or extrathoracic tumor 
was defined as distant metastasis. Locoregional tumor recur-
rence was defined as local recurrence as defined above plus 
any mediastinal or hilar lymph node metastasis.
Statistics
Overall survival was estimated using the Kaplan–Meier 
method. Time was taken between the date of surgery or the 
first fraction of SABR and date of death because of any cause 
or most recent date alive. To determine the role of covariables 
on overall survival, Cox regression analyses were performed. 
The following covariables were analyzed: treatment, age, sex, 
WHO performance score, Charlson comorbidity index, and 
tumor size. Significant factors were included in the multivari-
able models. For tumor recurrences and metastases, multivari-
able competing risk analyses with death and nontarget-type 
(first) recurrences as competing risk were performed. With 
this method, it is possible to correct for differences in inter-
current death and censoring because of clinical necessities. 
For example, occurrence of distant metastases was a compet-
ing risk for local recurrence, because imaging to identify local 
recurrence had been ceased in these patients. Thus, they were 
no longer at risk for local recurrence, a fact that is neglected 
in e.g., Cox regression analysis.
RESULTS
Patient, Tumor, and Treatment Characteristics
A total of 340 patients treated with surgery (n = 143) 
or SABR (n = 197) were included. Patient and treatment 
characteristics are shown in Table 1. Patients treated with 
surgery were 10 years younger, had a better performance 
status, less comorbidity, and better lung function tests, but 
tumor size and clinical stage were not different. FDG-PET/
CT was used for staging in all patients, endoscopic ultra-
sound and cervical mediastinoscopy were only used in 1% 
and 4%, respectively. Of note, in 85 of the surgical patients 
(59%), no tumor tissue had been obtained before surgery, 
although in 59 of them (69%) one or more biopsies had been 
attempted. In 154 of the SABR patients (78%), no tumor 
tissue was obtained.
Significantly more patients in the surgical cohort had 
an FDG-negative primary tumor (p < 0.001). The indication 
for resection in these cases had been based on spiculation and 
tumor growth on repeated CTs.
For surgical patients, the median hospital stay was 
9 days with a range of 3–111 days; in 90% of the patients, 
admission was less than 25 days. Stereotactic radiotherapy 
was exclusively administered in an outpatient setting.
In the surgical cohort, 15% of the patients received adju-
vant chemotherapy and 2% had postoperative radiotherapy for 
incomplete resection. Only a single patient (less than 1%) had 
adjuvant chemotherapy after SABR (p < 0.001).
Overall Survival
Median follow-up was 61 months. Age, performance 
status, comorbidity, tumor size, and treatment (surgery better 
than SABR) were highly significant predictive factors for sur-
vival at univariable analysis. After adjustment for the former 
factors, the difference in survival between surgery and SABR 
disappeared and the adjusted SABR versus surgery hazard 
ratio (HR) for overall survival was 1.07 (95% confidence 
interval [CI]: 0.74–1.54; p = 0.73). Of note, adjuvant therapy 
was not significantly related to overall survival. Unadjusted 
survival rates are shown in Table 2.
Tumor Recurrences and Occurrence 
of New Primaries
Local tumor control using the definition as described 
above was not different between SABR and surgery (adjusted 
sub-HR 1.21; 95% CI: 0.38–3.90; p = 0.75). Also for dis-
tant recurrence, no significant difference was found between 
both treatments (adjusted sub-HR 1.01; 95% CI: 0.56–1.84; 
p = 0.97). Treatment was not a significant factor for nodal 
tumor recurrence, but a trend for more nodal recurrences 
after SABR was found (adjusted sub-HR 2.17; 95% CI: 
0.91–5.17; p = 0.079).
Locoregional recurrences however—local or nodal or 
both together—were significantly more frequent after SABR 
compared with surgery (adjusted sub-HR 2.51; 95% CI: 1.10–
5.70; p = 0.03; Fig. 2).
Nodal and distant metastases, but not local recurrence, 
were significant independent predictive factors for survival 
(Table 3). The gross pattern of recurrence is displayed in 
Table 4. Unadjusted freedom-from-tumor-recurrence rates are 
shown in Table 2.
DISCUSSION
For medically inoperable patients with early stage 
NSCLC, SABR has evolved as the preferred treatment 
option.19,20 There are no randomized comparative trials avail-
able comparing surgery with SABR. However, such tri-
als would by definition be confined to operable patients. 
Therefore, the evolution of SABR has been mainly triggered 
by promising results for local tumor control after SABR.9–14,21 
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The range of reported survival rates after SABR is under-
standably variable because of patient selection.9 Moreover, 
little is known about the reasons for decreased survival after 
SABR: is it mainly because of comorbidity prompting medi-
cal inoperability, or is it because of differences in patterns 
of recurrence, or to both factors. To date, few studies have 
accepted the challenge to compare the outcomes of a SABR 
cohort directly with a surgical cohort.15–17,22
Typically, younger and fitter patients with less comor-
bidity and better lung function are offered surgery for 
solitary FDG-positive lung lesions highly suspicious for 
NSCLC, whereas the medically marginally operable or inop-
erable patient is offered SABR. In the absence of randomized 
data, comparative survival and recurrence data corrected for 
these well-known selection parameters are the second best 
source to possibly inform clinical decision making. To ana-
lyze survival rates, patterns of tumor recurrence after sur-
gery or SABR, and the impact of recurrence patterns upon 
survival, we studied a consecutive cohort of patients with 
cT1-2aN0M0 lung tumors highly suspicious for NSCLC. 
Our hypothesis was that SABR, when adjusting for group 
differences, would be equally effective as surgery in terms 
of tumor control and survival.
Our study indeed showed that survival depended on 
age, performance status, comorbidity, and tumor size, and 
that adjusted overall survival after surgery or SABR was not 
different. Prospective single arm trials involving SABR and 
retrospective analyses comparing SABR with surgery have 
found similar overall survival rates as we have found in our 
study.10–12,23 A recently published review showed even similar 






(n = 143) (n = 197)
No. of Patients (%) No. of Patients (%)
Age, years <0.001
  Median 67 77
  Range 40–84 52–93
Sex NS
  Men 96 (67) 143 (73)
  Women 47 (33) 54 (27)
WHO performance score <0.001
  0–1 143 (100) 155 (79)
  2–3 0 (0) 42 (21)
Charlson comorbidity index 0.012
  Median 2 2
  Range 0–5 0–5
  0–1 65 (45) 77 (39)
  ≥2 78 (55) 120 (61)
Current or former smoker 124 (87) 195 (99) <0.001
cTNM classification NS
  cT1aN0M0 61 (43) 71 (36)
  cT1bN0M0 22 (15) 55 (28)
  cT2aN0M0 60 (42) 71 (36)
Tumor size in mm, median 
  (range)
23 (5–50) 25 (5–50) NS
Tumor location NS
  Right upper lobe 51 (36) 73 (37)
  Right middle lobe 9 (6) 9 (5)
  Right lower lobe 25 (18) 26 (13)
  Left upper lobe 36 (25) 55 (28)
  Left lower lobe 22 (15) 34 (17)
Surgical treatment
  Pneumonectomy 5 (3)
  Lobectomy 110 (77)
  Bilobectomy 11(8)
  Wedge resection 17 (12)
pTNM classification
  pT1aN0M0 50 (35)
  pT1bN0M0 23 (16)
  pT2aN0M0 30 (21)
  upstaged to >stage I: 35 (24)
   pT1a-2aN1M0 16 (11)
   pT1a-2aN2M0 11 (8)
   pT2bN0-2M0 8 (6)
   Other tumora 2 (1)
   Benignb 3 (2)
SABR schedule
  3 × 20 Gy 95 (48)
  5 × 12 Gy 59 (30)
  8 × 7.5 Gy 39 (20)
  12 × 5 Gy 4 (2)
Follow-up time, months NS
  Median 61 61
  Range 43–84 43–79
aOne melanoma; one salivary gland tumor.
bOne solitary fibrous tumor; two localized infections.




1 Year 2 Years 3 Years 5 Years
Overall survival
  Surgery 91.6 80.4 68.5 58.2
  SABR 88.3 76.6 56.9 31.8
Free from local recurrence
  Surgery 98.3 97.2 96.0 93.0
  SABR 98.9 95.9 95.1 80.0
Free from lymph node recurrence
  Surgery 97.4 92.4 90.1 87.3
  SABR 92.0 88.3 88.3 78.7
Free from locoregional recurrence
  Surgery 97.4 92.4 90.1 87.3
  SABR 90.9 85.6 84.8 77.2
Free from distant recurrence
  Surgery 89.9 82.7 76.8 74.1
  SABR 91.5 85.0 80.6 65.9
Free from any recurrence
  Surgery 89.1 82.7 76.8 71.7
  SABR 84.7 77.8 72.7 57.4
Locoregional recurrence = local or lymph node or both.
SABR, stereotactic ablative radiotherapy.
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Also, the largest retrospective single-center SABR analysis 
showed comparable survival and recurrence rates.21
Lagerwaard et al.13, who analyzed potentially operable 
patients having received SABR, found higher overall survival 
rates compared with our study because of selection of a fitter 
patient group. An even higher 5-year overall survival of 69.5% 
was found by Onishi et al.24, however, this was a cohort of 87 
medically operable Japanese patients treated with SABR, who 
show better survival very consistently in most studies involv-
ing lung cancer.
In our study, we defined local tumor recurrence as recur-
rence in the same lobe as the primary tumor or at the ipsilateral 
hilus, and locoregional recurrence as including in addition the 
contralateral hilus or any mediastinal lymph node metastases. 
Tumor recurrence definitions are not used consistently in the 
literature. In most stereotactic radiotherapy or local-and-limited-
resection studies, local recurrence is defined more restrictive as 
recurrence at the exact location of the primary tumor.23 Such a 
definition precludes reasonable comparisons with lobectomy 
series. In our study, no difference between the treatment groups 
was found for local recurrence (using our definition) or distant 
metastases. In contrast to other studies that found no increased 
locoregional recurrence rate after SABR compared with resec-
tion,16,22 we observed a trend toward more nodal recurrences 
after SABR and significantly more locoregional tumor recur-
rences after SABR compared with surgery. In keeping with this 
result, 24% (19% were solely because of hilar and/or medias-
tinal lymph nodes) of our FDG-PET-CT-based clinical stage I 
patients were upstaged postoperatively to higher stages based on 
the resected specimen (Table 1). This seems to be quite high and 
may partly be because of an earlier generation PET machine that 
was used during the time of the study, but it is in line with recent 
data in the literature.16,25,26 This stresses the importance of opti-
mal lymph node staging especially if the nodes are not sampled 
at treatment (i.e., SABR or wedge resection). Even though our 
patients had undergone FDG-PET, still a number of them will 
have harvested latent metastases in hilar or mediastinal nodes, 
which were not treated with SABR. A major argument for sur-
gery thus remains the remaining uncertainty about hilar (or 
mediastinal) lymph node involvement despite negative CT and 
FDG-PET scans. It is well known that small lymph node metas-
tases are not detected by PET. A recently published study showed 
that the sensitivity, specificity, and accuracy of 18F-FDG-PET/
CT for assessing mediastinal lymph node metastasis with a 
short-axis diameter of less than 15 mm is still limited.27 As high 
as 18% of occult lymph node metastases in an FDG-negative 
hilus and mediastinum were found in another recent study, and 
SUV and size of primary tumor were factors predicting node-
positivity.28 Therefore, to improve locoregional tumor control in 
patients with stage I NSCLC who are eligible for SABR, using 
new-generation PET and even minimally invasive mediastinal 
staging using E(B)US with fine needle aspiration or even medi-
astinoscopy should be carefully considered to spare them poten-
tial undertreatment because of neglect of nodal metastases.
A limitation of our study is its retrospective design. 
However, we double-checked data using information from 
the general practitioner and the Municipal Personal Records 
Database in addition to patient files. A serious limitation of 
the Charlson comorbidity score is that no distinction is made 
in severity of the comorbidity, e.g., between mild or severe 
pulmonary problems. Another limitation is because of use of 
an out-dated radiation dose calculation algorithm during the 
study period (pencil-beam calculation with heterogeneity cor-
rection). Nowadays, Monte Carlo or collapsed cone algorithms 
are used resulting in higher SABR doses compared with the 
doses actually delivered during the studied period. Therefore, 
locoregional tumor control with SABR might have improved in 
the last couple of years. The strength of this study is the direct 
comparison of both survival and patterns of tumor recurrence 





Variable Hazard Ratio 95% CI p Value
Age, per year 1.041 1.02–1.06 <0.001
Charlson comorbidity index, ≥2 vs. 0–1 1.453 1.07–1.98 0.017
WHO performance score, ≥2 vs. 0–1 2.025 1.35–3.04 0.001
Tumor size, per mm 1.013 1.00–1.03 0.061
Treatment, SABR vs. surgery 0.98 0.68–1.41 0.915
Local recurrence 0.996 0.53–1.89 0.991
Lymph node recurrence 2.163 1.34–3.48 0.002
Distant recurrence 2.123 1.52–2.97 <0.001
WHO, World Health Organization; SABR, stereotactic ablative radiotherapy; CI, confidence interval.
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with a very long follow-up. Indications were discussed at a mul-
tidisciplinary tumor board, all patients were staged with FDG-
PET/CT, and analyses were based on clinical, not postoperative 
pathological staging information, which would skew the com-
parison. Analyses were corrected for the factors upon which 
patient selection for treatment had been performed and pat-
terns of recurrences were analyzed taking competing risks into 
account. In conclusion, patients with NSCLC at clinical stage I 
treated with surgery were 10 years younger, fitter and had less 
comorbidities than those treated with SABR. Adjusted overall 
survival was similar between surgery and SABR, but SABR 
yielded worse locoregional tumor control compared with sur-
gery. This was because of more nodal failures after SABR 
compared with surgery. SABR is a tailor-made treatment for 
patients unfit for surgery, but optimal mediastinal and hilar 
staging remains essential for optimizing treatment decisions.
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TABLE 4.  Patterns of Failure per Treatment Group (n = 340)
Surgery SABR
(n = 143) (n = 197)
Type of Recurrence No. of Patients (%) No. of Patients (%)
Local 6 (4) 11 (6)
Lymph node 12 (8) 25 (13)
Local or node or both 12 (8) 30 (15)
Distant 29 (20) 41 (21)
Any 31 (22) 57 (29)
No recurrence 112 (78) 140 (71)
Local, recurrence in lobe of primary tumor or ipsilateral hilus; lymph node, 
recurrence in any hilar or mediastinal lymph node; local or node or both = locoregional; 
distant, recurrence outside locoregional region; any, any of the above recurrence types.
SABR, stereotactic ablative radiotherapy.
